<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042717</url>
  </required_header>
  <id_info>
    <org_study_id>GCO # 09-0824</org_study_id>
    <nct_id>NCT01042717</nct_id>
  </id_info>
  <brief_title>Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection</brief_title>
  <official_title>Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shi, Patricia, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shi, Patricia, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether it is safe and effective to collect&#xD;
      peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after&#xD;
      administration of plerixafor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current FDA-approved timing for plerixafor is approximately 11 hours prior to apheresis.&#xD;
      This is a logistical problem, since plerixafor should be administered by a health care&#xD;
      provider, given the risk of hypotension with administration. The primary purpose of this&#xD;
      study is, in autologous donors with non-Hodgkins lymphoma and multiple myeloma undergoing&#xD;
      hematopoietic progenitor cell mobilization with plerixafor and G-CSF, to determine whether&#xD;
      the dosing interval can be increased to 16 hours prior to apheresis. Patients will be&#xD;
      admitted to a special clinical research center on the 4th day of G-CSF administration, where&#xD;
      the peripheral blood CD34+ count will be measured every 2 hours after plerixafor&#xD;
      administration at 5 pm until 9 AM the following day, at which time apheresis will commence.&#xD;
      The hypothesis is that plerixafor administration 16 hours prior to apheresis is as safe and&#xD;
      effective as plerixafor administration at 11 hours prior to apheresis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of donors obtaining a minimum CD34+ cell dose of 2 x 106/kg actual recipient weight within 2 days of collection</measure>
    <time_frame>After collection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median and average neutrophil and platelet engraftment</measure>
    <time_frame>After stem cell infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plerixafor-related toxicities</measure>
    <time_frame>1 month after stem cell infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkins Lymphoma</condition>
  <arm_group>
    <arm_group_label>Plerixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plerixafor 16 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Plerixafor administered at 16 hours prior to apheresis</description>
    <arm_group_label>Plerixafor</arm_group_label>
    <other_name>Mozobil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Autologous donors age 18 to 75 years with NHL or MM scheduled to undergo peripheral&#xD;
             blood stem cell collection as part of standard clinical care. Biopsy-confirmed&#xD;
             diagnosis of NHL or MM is to have been done prior to the first mobilization.&#xD;
&#xD;
          2. In first or second CR or PR&#xD;
&#xD;
          3. ECOG performance status of 0 or 1&#xD;
&#xD;
          4. WBC count greater than 2.5 x 10e9/1&#xD;
&#xD;
          5. Absolute PMN count greater than 1.5 x 10e9/1&#xD;
&#xD;
          6. PLT count greater than 100 x 10e9/1&#xD;
&#xD;
          7. Serum creatinine less than or equal to 2.2 mg/dl&#xD;
&#xD;
          8. SGOT, SGPT, and total bilirubin less than 2.5 X upper limit of normal (ULN)&#xD;
&#xD;
          9. Cardiac and pulmonary status sufficient to undergo apheresis and transplantation&#xD;
&#xD;
         10. Negative for HIV&#xD;
&#xD;
         11. 4 weeks since last cycle of chemotherapy. (Rituximab, thalidomide, dexamethasone, and&#xD;
             bortezomib are not considered chemotherapy for the purpose of the study)&#xD;
&#xD;
         12. Patients of childbearing potential agree to use an approved form of contraception&#xD;
&#xD;
         13. Recovered from all acute toxic effects of prior chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Comorbid condition which renders patient, in view of the investigators, at high risk&#xD;
             of treatment complications&#xD;
&#xD;
          2. Failed previous stem cell collections or collection attempts&#xD;
&#xD;
          3. Less than 6 weeks of carmustine prior to the 1st dose of G-CSF&#xD;
&#xD;
          4. Received GM-CSF or pegfilgrastim within 3 weeks prior to the 1st dose of G-CSF for&#xD;
             mobilization&#xD;
&#xD;
          5. Received G-CSF within 14 days prior to the 1st dose of G-CSF for mobilization&#xD;
&#xD;
          6. Active CNS involvement&#xD;
&#xD;
          7. Active brain metastases or carcinomatous meningitis&#xD;
&#xD;
          8. Bone marrow involvement greater than 20 percent&#xD;
&#xD;
          9. Received radiation therapy to the pelvis&#xD;
&#xD;
         10. Post-transplant chemotherapy and/or radiation therapy below the diaphragm is&#xD;
             anticipated&#xD;
&#xD;
         11. Received prior radio-immunotherapy with Zevalin or Bexxar&#xD;
&#xD;
         12. Fever (temperature greater than 38 C/100.4 F)&#xD;
&#xD;
         13. Received bone-seeking radionuclides (e.g., holmium)&#xD;
&#xD;
         14. A residual acute medical condition resulting from prior chemotherapy&#xD;
&#xD;
         15. Active brain metastases or myelomatous meningitis&#xD;
&#xD;
         16. Received thalidomide, dexamethasone and/or Velcade within 7 days prior to the first&#xD;
             dose of G-CSF&#xD;
&#xD;
         17. Received Revlimid within 3 weeks prior to the first dose of G-CSF&#xD;
&#xD;
         18. Received greater than 6 cycles of Revlimid&#xD;
&#xD;
         19. Positive pregnancy test or lactating&#xD;
&#xD;
         20. Active infection requiring antibiotic treatment&#xD;
&#xD;
         21. Abnormal ECG with clinically significant rhythm disturbance (ventricular arrhythmias),&#xD;
             or other conduction abnormality in the last year that in the opinion of the&#xD;
             investigator warrants exclusion of the subject from the trial.&#xD;
&#xD;
         22. Patients who previously received experimental therapy within 4 weeks of enrolling in&#xD;
             this protocol or who are currently enrolled in another experimental protocol during&#xD;
             the mobilization phase.&#xD;
&#xD;
         23. Patients whose apheresis product will be further selected and purified.&#xD;
&#xD;
         24. Prior autologous or allogeneic transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia A Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia A Shi, MD</last_name>
      <phone>212-241-9237</phone>
      <email>patricia.shi@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Luis M Isola, MD</last_name>
      <phone>212-241-6021</phone>
      <email>luis.isola@msnyuhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia A Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis M Isola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a609018.html</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH, Dale DC. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005 Mar;45(3):295-300.</citation>
    <PMID>15752146</PMID>
  </reference>
  <reference>
    <citation>DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.</citation>
    <PMID>19720922</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>September 26, 2011</last_update_submitted>
  <last_update_submitted_qc>September 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shi, Patricia, M.D.</investigator_affiliation>
    <investigator_full_name>Patricia Shi</investigator_full_name>
    <investigator_title>Assistant Professor, Hematology-Oncology</investigator_title>
  </responsible_party>
  <keyword>plerixafor</keyword>
  <keyword>autologous transplantation</keyword>
  <keyword>hematopoietic stem cell mobilization</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>non-Hodgkins lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

